A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Greater than or equal to 18 years of age
• HPV associated carcinomas
• Patients must have at least one measurable lesion defined by RECIST 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Locations
Other Locations
China
The affiliated hosptial of qingdao university
RECRUITING
Qingdao
Contact Information
Primary
Hongying Lv
qdlhytiger@163.com
+86 18661805217
Time Frame
Start Date: 2023-08-02
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 18
Treatments
Experimental: SCG142 TCR-T cells
Monotherapy of SCG142
Related Therapeutic Areas
Sponsors
Leads: The Affiliated Hospital of Qingdao University